VISK on OTC
American pharmaceutical company
Enzon Pharmaceuticals, Inc. is a pharmaceutical company.3 From Wikipedia, CC BY-SA 4.0
Price unavailable
Last updated Oct 19, 2026.
Compare with Opthea Ltd, Allogene Therapeutics, Inc. or Senti Biosciences Holdings, Inc., or pick any stock.
See how the biggest companies compare on our leaderboards
Enzon Pharmaceuticals, Inc. is a pharmaceutical company. Its headquarters is in Piscataway, New Jersey. The company is a publicly traded company on NASDAQ under the symbol "ENZN". It's also doing marketing works in Asia areas such as China. In 2012, the company orally presented in Nanjing, China about the symposium of its drug delivery systems, which help improve therapeutic molecules' pharmaceutical properties.3
From the company’s reports to the SEC. Every number links to the filing it came from.
Out of $26.0K in revenue.7
Out of $1.1M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.7
Every line of the income statement as filed: the last 2 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Royalties and milestones, net | $26.0K | |
| Total revenues | $26.0K | |
| General and administrative | $1.4M | $1.4M |
| Transaction expenses | $4.0M | |
| Total operating expenses | $5.3M | $1.4M |
| Operating loss | -$5.3M | -$1.3M |
| Interest and dividend income | $1.9M | $2.5M |
| (Loss) income before income tax expense | -$3.4M | $1.1M |
| Income tax expense | -$19.0K | -$347.0K |
| Net (loss) income | -$3.4M | $778.0K |
| Dividends on Series C Preferred Stock | -$2.1M | -$1.3M |
| Net loss available to common shareholders | -$5.5M | -$497.0K |
| Basic (in dollars per share) | -$0.07 | -$0.01 |
| Diluted (in dollars per share) | -$0.07 | -$0.01 |
| Weighted average number of common shares - basic (in shares) | 74.2M shares | 74.2M shares |
| Weighted average number of common shares - diluted (in shares) | 74.2M shares | 74.2M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $42.6M | $46.9M | |
| Other current assets | $239.0K | $293.0K | |
| Total current assets | $42.8M | $47.2M | |
| Deferred tax asset | $17.0K | ||
| Total assets | $42.8M | $47.2M | |
| Accounts payable | $331.0K | $331.0K | |
| Accrued expenses and other current liabilities | $400.0K | $72.0K | |
| Dividends payable on Series C preferred stock | $1.3M | ||
| Total current liabilities | $731.0K | $1.7M | |
| Common stock - $0.01 par value, authorized 170,000,000 shares; issued and outstanding 74,214,603 shares at December 31, 2025 and 2024 | $742.0K | $742.0K | |
| Additional paid-in capital | $70.0M | $72.2M | |
| Accumulated deficit | -$73.3M | -$69.9M | |
| Total stockholders' (deficit) equity | -$2.5M | $3.0M | -$3.5M |
| Total liabilities, mezzanine equity and stockholders' (deficit) equity | $42.8M | $47.2M | |
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | |
| Preferred stock, shares authorized | 3.0M shares | 3.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | |
| Common stock, shares authorized | 170.0M shares | 170.0M shares | |
| Common stock, shares issued | 74.2M shares | 74.2M shares | |
| Common stock, shares outstanding | 74.2M shares | 74.2M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $42.6M | $46.9M | |
| Other current assets | $239.0K | $293.0K | |
| Total current assets | $42.8M | $47.2M | |
| Deferred tax asset | $17.0K | ||
| Total assets | $42.8M | $47.2M | |
| Accounts payable | $331.0K | $331.0K | |
| Accrued expenses and other current liabilities | $400.0K | $72.0K | |
| Dividends payable on Series C preferred stock | $1.3M | ||
| Total current liabilities | $731.0K | $1.7M | |
| Common stock - $0.01 par value, authorized 170,000,000 shares; issued and outstanding 74,214,603 shares at December 31, 2025 and 2024 | $742.0K | $742.0K | |
| Additional paid-in capital | $70.0M | $72.2M | |
| Accumulated deficit | -$73.3M | -$69.9M | |
| Total stockholders' (deficit) equity | -$2.5M | $3.0M | -$3.5M |
| Total liabilities, mezzanine equity and stockholders' (deficit) equity | $42.8M | $47.2M | |
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | |
| Preferred stock, shares authorized | 3.0M shares | 3.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | |
| Common stock, shares authorized | 170.0M shares | 170.0M shares | |
| Common stock, shares issued | 74.2M shares | 74.2M shares | |
| Common stock, shares outstanding | 74.2M shares | 74.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net (loss) income | -$3.4M | $778.0K |
| Deferred income taxes | $17.0K | $342.0K |
| Decrease in other current assets | $54.0K | $38.0K |
| Increase (decrease) in accrued expenses and other current liabilities | $328.0K | -$36.0K |
| Net cash (used in) provided by operating activities | -$3.0M | $1.1M |
| Preferred stock dividend payments | -$1.3M | -$1.3M |
| Net cash used in financing activities | -$1.3M | -$1.3M |
| Net decrease in cash | -$4.3M | -$153.0K |
No quarter-by-quarter statement was filed.
Enzon Pharmaceuticals, Inc started its earliest business in 1981. Now, the focus of the company is mainly on development and production of drugs for cancer patients. It is also actively researching on improving the chemical attachment of PEG to help provide antibodies in molecules.
In 2010, Enzon Pharmaceuticals, Inc.sold its specialty pharmaceutical business to the sigma-tau Group (sigma-tau).
From Wikipedia’s article on Enzon Pharmaceuticals, shared under CC BY-SA 4.0.6
Who has led Enzon Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.
The products of Enzon Pharmaceuticals, Inc include four principal compounds of different clinical development, as well as several novel mRNA antagonists in preclinical research.
In July 2012, Enzon Pharmaceuticals presented the result from pre-clinical studies about human interferon-beta-1b (IFN-β-1b) and an anti-TNF-α antibody fragment (Fab) through releasable PEGylation at the 39th Annual Meeting & Exposition of the Controlled Release Society.In June 2012, Enzon Pharmaceuticals presented the Phase I study of PEG-SN38 in children with recurrent or refractory neuroblastoma and other solid tumors at the 2012 Advances in Neuroblastoma Research Conference. In the same month, the company presented the Phase II study in which PEG-SN38 demonstrated notable activity in patients with previously treated metastatic breast at the American Society of Clinical Oncology Meeting.In May 2012, Enzon Pharmaceuticals reached a strategic partnership using Enzon's PEGylation linker technology and PEG-SN38 (EZN-2208) in China.
From Wikipedia’s article on Enzon Pharmaceuticals, shared under CC BY-SA 4.0.6
130 filings to the SEC since October 2021: 8 annual reports, 15 quarterly reports, 33 major events, 18 insider forms, 6 large holders, 50 other. The latest 20:
The 130 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 16, 2023 | READ RANDOLPH CDirector | Buy | 84,550 | $0.14 | $11.8K | Form 4 |
| Jun 14, 2023 | READ RANDOLPH CDirector | Buy | 15,000 | $0.13 | $1.9K | Form 4 |
From Forms 4 filed with the SEC.
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
The numbers on this page point here. Each one links to the record it came from.